Summit Therapeutics is trading 4.62% up now at $15.27 after partner Akeso reported statistically significant overall-survival benefits for ivonescimab versus pembrolizumab in the Phase III HARMONi-2 trial.
- Summit separately highlighted the positive results on September 2, 2026, supporting renewed investor interest in its lead oncology asset.
- The move appears company-specific rather than driven by broader markets, which are largely mixed.